结核分枝杆菌Ag85复合物相关疫苗研究进展

摘要/Abstract

摘要： 目前全球TB疫情呈上升趋势，而惟一使用的结核病疫苗——BCG的保护效力大不如前，因此新型结核病疫苗的开发迫在眉睫。利用Ag85复合物在Mtb感染中具有明显保护性效应为基础而研制的疫苗受到广泛关注。笔者对Ag85复合物相关亚单位疫苗、重组BCG和基因疫苗研究取得的成果进行综述，结果表明少数Ag85复合物相关疫苗的保护作用超过BCG，某些新疫苗作为初种疫苗给予新生儿、儿童和青少年接种是安全、有效的；作为增强剂给予成人接种，可以提高机体免疫力；某些疫苗与化疗药物联合可以提高机体的免疫力，提高化疗效果，但能否取代BCG尚需大规模临床实验证实。

关键词: 酰基转移酶类, 抗原, 细菌, 细菌蛋白质类, 疫苗, 亚单位, 卡介苗, 疫苗, DNA, 结核/预防和控制

Abstract: Nowadays,the prevalence and incidence of tuberculosis are on the rise in the whole world.However,the maximum protection of the only used tuberculosis vaccine-Bacilli Calmette-Guérin is limited.Therefore,it is very urgent to research and develop a new effective vaccine.Ag85 cantigen 85 complex has received a great attention in the field of new vaccine against tuberculosis because it can enhance experimental animals’immunity.This article introduced some achievements about Ag85 complex vaccines.The results showed that researchers have demonstrated that the protection of a few vaccines exceed that of traditional BCG. As a priming vaccine,it is safety and effective for newborns, children and youngsters. As a booster regimen to adults,it can enhance the anti-tuberculosis ability. Moreover, the vaccine combined with chemotherapy can improve the immunity and curative effect.But it needs more clinical trical evidence to demonstrate wether if it could replace traditional BCG.

Key words: Acyltransferases, Antigens, bacterial, Bacterial proteins, Vaccines, subunit, BCG vaccine, Vaccines, DNA, Tuberculosis/prevention &, control

柴雪敏黎友伦. 结核分枝杆菌Ag85复合物相关疫苗研究进展[J]. 中国防痨杂志, 2013, 35(4): 282-285.

. The research progression of tuberculosis vaccine on antigen85 complex[J]. Chinese Journal of Antituberculosis, 2013, 35(4): 282-285.

参考文献

［1］ Rowland R, McShane H. Tuberculosis vaccines in clinical trials. Expert Rev Vaccines,2011,10(5):645-658.
［2］尹文东,于庭,梁艳,等.结核分枝杆菌重组Ag85A、Ag85B蛋白免疫原性的研究.中国实验诊断学,2011,15(10):1618-1621.
［3］ Lu D, Garcia-Contreras L, Muttil P,et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.AAPS J, 2010,12(3):338-347.
［4］ Giri PK, Verma I, Khuller GK. Adjunct immunotherapy with Ag85 complex proteins based subunit vaccine in a murine model of Mycobacterium tuberculosis infection. Immunotherapy, 2009,1(1):31-37.
［5］黎友伦，罗永艾,王国治.细胞因子及其受体在结核免疫中的作用.国外医学内科学分册,2005,32(4):146-149.
［6］师长宏,范雄林,柏银兰,等.结核分枝杆菌Ag85B-ESAT6 融合蛋白在小鼠体内诱导的免疫应答及其保护力.第四军医大学学报,2004,25 (18):1633-1636.
［7］ Langermans JA, Doherty TM, Vervenne RA,et al.Protection of macaques against Mycobacterium tuberculosis infection by a subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.Vaccine,2005,23(21):2740-2750.
［8］ McShane H, Pathan AA, Sander CR, et al.Recombinant mo-dified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.Nat Med,2004,10(11):1240-1244.
［9］ Scriba TJ, Tameris M, Mansoor N, et al.Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4⁺ T cells.Eur J Immunol,2010,40(1):279-290.
［10］ Aeras, University of Oxford,European, Developing Countries Clinical Trials Partnership (EDCTP). Protective efficacy against tuberculosis (TB) disease, safety, and immunogenicity of MVA85A/AERAS-485 in HIV-infected adults［EB/OL］.［2012-11-25］.http://clinicaltrials.gov/ct2/show/NCT01151189?term=MVA+85A&rank=2.htm.
［11］ van Dissel JT, Soonawala D, Joosten SA, et al.Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection.Vaccine,2011,3(29):2100-2109.
［12］ Aeras, Crucell Holland BV. Safety and immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmerre-Guerin(BCG)-vaccinated adults［EB/OL］.［2012-11-15］.http://clinicaltrials.gov/ct2/show/NCT01017536?term=AERAS-402&rank=2.htm.
［13］ Horwitz MA, Harth G. A new vaccine against tuberculosis affords greater survival after challenge than the current vaccine in the guinea pig model of pulmonary tuberculosis.Infect Immun,2003,71(4):1672-1679.
［14］ Hoft DF, Blazevic A, Abate G, et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis,2008,198(10):1491-1501.
［15］ Sugawara I, Sun L, Mizuno S, et al. Protective efficacy of recombinant BCG Tokyo (Ag85A) in rhesus monkeys (Macaca mulatta) infected intratracheally with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb),2009,89(1):62-67.
［16］ Jain R, Dey B, Dhar N, et al.Enhanced and enduring protection against tuberculosis by recombinant BCG-Ag85C and its association with modulation of cytokine profile in lung.PLoS One,2008,3(12):e3869.
［17］ Xu Y, Liu W, Shen H, et al.Recombinant Mycobacterium bovis BCG expressing the chimeric protein of antigen 85B and ESAT-6 enhances the Th1 cell-mediated response.Clin Vaccine Immunol,2009,16(8):1121-1126.
［18］王平,王丽梅,张薇,等.结核分枝杆菌Ag85B-ESAT-6融合蛋白重组耻垢分枝杆菌对小鼠的免疫原性研究.中国防痨杂志,2012,34(3):145-149.
［19］张灵霞,吴雪琼,董恩军.四种卡介苗重组疫苗对结核病的预防作用.实用医学杂志,2011,27(12):2115-2117.
［20］ Chang-hong S, Xiao-wu W, Hai Z, et al.Immune responses and protective efficacy of the gene vaccine expressing Ag85B and ESAT6 fusion protein from Mycobacterium tuberculosis.DNA Cell Biol,2008,27(4):199-207.
［21］ Fan X, Gao Q, Fu R.Differential immunogenicity and protective efficacy of DNA vaccines expressing proteins of Mycobacterium tuberculosis in a mouse model. Microbiol Res,2009,164(4):374-382.
［22］吴雪琼，李洪敏，史迎昌，等．结核分枝杆菌ＤＮＡ疫苗抗结核作用的研究．中国生物制品学杂志，2002,1（6）：340-345.
［23］ Liang Y, Wu X, Zhang J, et al.The treatment of mice infected with multi-drug-resistant Mycobacterium tuberculosis using DNA vaccines or in combination with rifampin.Vaccine, 2008,26(35):4536-4540.
［24］ Liang Y,Wu X,Zhang J，et al.Treatment of multi-drug-resis-tant tuberculosis in mice with DNA vaccines alone or incombination in mice chemotherapeutic drugs.Scand J Immunol，2011,74（1）：42-46.
［25］梁艳,吴雪琼,张俊仙,等.结核分枝杆菌Ag85A/ESAT-6嵌合型质粒DNA疫苗和抗结核药物联合治疗小鼠耐药结核病的效果研究.中国防痨杂志，2007,29（5):382-385.
［26］胡静,吴雪琼,王丽华,等.结核分支杆菌Ag85B DNA疫苗构建、免疫原性及其保护效力.科学技术与工程,2006，6(13):1765-1770.
［27］ Tanghe A, D’Souza S, Rosseels V, et al. Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting. Infect Immun,2001,69(5):3041-3047.

[1]	赵爱华, 康万里, 王国治, 高正伦, 都伟欣, 卢锦标, 沈小兵, 苏城, 徐苗, 郑素华. 重组结核分枝杆菌11kDa蛋白鉴别潜伏性结核感染与卡介苗接种的研究[J]. 中国防痨杂志, 2020, 42(8): 821-825.
[2]	杨鲁琦, 沈鸣逸, 沙巍, 陈颖盈, 王颖. 卡介苗的免疫保护机制及其改造策略进展[J]. 中国防痨杂志, 2020, 42(8): 863-868.
[3]	陈柠, 孙琳, 申阿东, 何秋水. 卡介苗接种后发生感染的可能原因研究现况[J]. 中国防痨杂志, 2020, 42(8): 869-873.
[4]	陈柠, 孙琳, 申阿东, 何秋水. 卡介苗非特异性保护作用研究进展[J]. 中国防痨杂志, 2020, 42(10): 1128-1133.
[5]	赵爱华,王国治,付丽丽,徐苗. 国内外结核病预防用卡介苗质量标准比较[J]. 中国防痨杂志, 2018, 40(10): 1125-1128.
[6]	王丁丁，付丽丽，寇丽杰，等.. 豚鼠模型卡介苗接种所引发的淋巴结炎致病菌的分离和鉴定[J]. 中国防痨杂志, 2016, 38(3): 209-214.
[7]	赵爱华，徐苗，郑素华，等. 针对世界卫生组织对卡介苗两次文件立场观点差异的探讨[J]. 中国防痨杂志, 2016, 38(2): 87-89.
[8]	方勇，肖和平. 潜伏性结核感染的诊治进展[J]. 中国防痨杂志, 2016, 38(2): 144-147.
[9]	肖和平. 立法管理结核病传染源刻不容缓[J]. 中国防痨杂志, 2015, 37(9): 921-922.
[10]	沈静，赵雁林，逄宇，张舜，杜昌廷，刘洁. 131株耐多药结核分枝杆菌对利福布丁与利福平交叉耐药的研究[J]. 中国防痨杂志, 2015, 37(4): 377-382.
[11]	李涛，成诗明，杜昕. 全国结核病防治工作模式与患者发现和治疗管理水平分析[J]. 中国防痨杂志, 2015, 37(1): 30-34.
[12]	刘银萍，王全立，张俊仙，梁艳，阳幼荣，白雪娟，吴雪琼. 结核分枝杆菌Rv1419蛋白抗原表位的预测[J]. 中国防痨杂志, 2015, 37(1): 52-55.
[13]	冉兵，蔡林. 基因芯片检测耐利福平结核分枝杆菌准确性的Meta分析[J]. 中国防痨杂志, 2015, 37(1): 56-65.
[14]	艾静文，阮巧玲，张文宏. 结核分枝杆菌潜伏感染预防性治疗的进展[J]. 中国防痨杂志, 2015, 37(1): 80-85.
[15]	姜世闻，刘小秋. 我国流动人口结核病防治工作的进展与展望[J]. 中国防痨杂志, 2014, 36(9): 798-801.